Free Trial
NYSE:SSTK

Shutterstock Q4 2024 Earnings Report

Shutterstock logo
$13.00 +3.61 (+38.45%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$13.13 +0.13 (+1.00%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure EPS Results

Actual EPS
$0.67
Consensus EPS
$0.92
Beat/Miss
Missed by -$0.25
One Year Ago EPS
$0.72

uniQure Revenue Results

Actual Revenue
$250.30 million
Expected Revenue
$254.16 million
Beat/Miss
Missed by -$3.86 million
YoY Revenue Growth
+15.20%

uniQure Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, February 25, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Shutterstock's Q1 2025 earnings is scheduled for Thursday, May 1, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

uniQure Earnings Headlines

Shutterstock: Don't Fear AI Too Much
100-year-old investment secret predicts what?!
A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust, the 2008 crisis, and the crash of 2020. Now, it’s flashing again. Eliza Lasky of Weiss Advocate reveals what this forgotten signal says about the next big move — and how smart investors are preparing.
See More Shutterstock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email.

About uniQure

uniQure (NASDAQ:QURE) N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

View uniQure Profile

More Earnings Resources from MarketBeat